APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cell Immunotherapy Platform

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cell Immunotherapy Platform Market Analysis and Forecast 2026-2032

5 June 2026189 pages

Choose your research edition.

Industry ResearchCell Immunotherapy Platform Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Cell Immunotherapy Platform Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Cell Immunotherapy Platform Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cell Immunotherapy Platform Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Cell Immunotherapy Platform Market Analysis and Forecast 2026-2032189 pages · $4,950 USD

Market perspective

The global Cell Immunotherapy Platform market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Cell Immunotherapy Platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cell Immunotherapy Platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cell Immunotherapy Platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cell Immunotherapy Platform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Cell Immunotherapy Platform include Kite Pharma, Novartis, Bristol Myers Squibb, Gilead Sciences, Bluebird Bio, Celyad Oncology, Autolus Therapeutics, Legend Biotech and Celltrion, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Cell Immunotherapy Platform, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cell Immunotherapy Platform, also provides the revenue of main regions and countries. Of the upcoming market potential for Cell Immunotherapy Platform, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cell Immunotherapy Platform revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cell Immunotherapy Platform market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Cell Immunotherapy Platform revenue, projected growth trends, production technology, application and end-user industry.

Cell Immunotherapy Platform Segment by Company

Kite Pharma

Novartis

Bristol Myers Squibb

Gilead Sciences

Bluebird Bio

Celyad Oncology

Autolus Therapeutics

Legend Biotech

Celltrion

Cell Immunotherapy Platform Segment by Type

Autologous Immune Cell Therapy

Allogeneic Immune Cell Therapy

Cell Immunotherapy Platform Segment by Application

Immunotherapy Industry

Biopharmaceutical Industry

Others

Cell Immunotherapy Platform Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell Immunotherapy Platform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cell Immunotherapy Platform and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell Immunotherapy Platform.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Cell Immunotherapy Platform in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Cell Immunotherapy Platform company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cell Immunotherapy Platform revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cell Immunotherapy Platform Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Autologous Immune Cell Therapy Major Player Table 3. Allogeneic Immune Cell Therapy Major Player Table 4. Global Cell Immunotherapy Platform Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Immunotherapy Industry Major Player Table 6. Biopharmaceutical Industry Major Player Table 7. Others Major Player Table 8. Cell Immunotherapy Platform Industry Trends Table 9. Cell Immunotherapy Platform Industry Drivers Table 10. Cell Immunotherapy Platform Industry Opportunities and Challenges Table 11. Cell Immunotherapy Platform Industry Restraints Table 12. Global Cell Immunotherapy Platform Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Cell Immunotherapy Platform Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Cell Immunotherapy Platform Market Share by Region (2021-2026) Table 15. Global Cell Immunotherapy Platform Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Cell Immunotherapy Platform Market Share by Region (2027-2032) Table 17. Global Cell Immunotherapy Platform Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Cell Immunotherapy Platform Revenue Market Share by Players (2021-2026) Table 19. Global Cell Immunotherapy Platform Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Cell Immunotherapy Platform Key Players Headquarters & Area Served Table 21. Global Cell Immunotherapy Platform Players, Product Type & Application Table 22. Global Cell Immunotherapy Platform Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Cell Immunotherapy Platform by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Cell Immunotherapy Platform Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Cell Immunotherapy Platform Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Cell Immunotherapy Platform Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Cell Immunotherapy Platform Revenue Market Share by Type (2021-2026) Table 29. Global Cell Immunotherapy Platform Revenue Market Share by Type (2027-2032) Table 30. Global Cell Immunotherapy Platform Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Cell Immunotherapy Platform Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Cell Immunotherapy Platform Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Cell Immunotherapy Platform Revenue Market Share by Application (2021-2026) Table 34. Global Cell Immunotherapy Platform Revenue Market Share by Application (2027-2032) Table 35. Kite Pharma Company Information Table 36. Kite Pharma Business Overview Table 37. Kite Pharma Cell Immunotherapy Platform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Kite Pharma Cell Immunotherapy Platform Product Portfolio Table 39. Kite Pharma Recent Development Table 40. Novartis Company Information Table 41. Novartis Business Overview Table 42. Novartis Cell Immunotherapy Platform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Novartis Cell Immunotherapy Platform Product Portfolio Table 44. Novartis Recent Development Table 45. Bristol Myers Squibb Company Information Table 46. Bristol Myers Squibb Business Overview Table 47. Bristol Myers Squibb Cell Immunotherapy Platform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Bristol Myers Squibb Cell Immunotherapy Platform Product Portfolio Table 49. Bristol Myers Squibb Recent Development Table 50. Gilead Sciences Company Information Table 51. Gilead Sciences Business Overview Table 52. Gilead Sciences Cell Immunotherapy Platform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Gilead Sciences Cell Immunotherapy Platform Product Portfolio Table 54. Gilead Sciences Recent Development Table 55. Bluebird Bio Company Information Table 56. Bluebird Bio Business Overview Table 57. Bluebird Bio Cell Immunotherapy Platform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Bluebird Bio Cell Immunotherapy Platform Product Portfolio Table 59. Bluebird Bio Recent Development Table 60. Celyad Oncology Company Information Table 61. Celyad Oncology Business Overview Table 62. Celyad Oncology Cell Immunotherapy Platform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Celyad Oncology Cell Immunotherapy Platform Product Portfolio Table 64. Celyad Oncology Recent Development Table 65. Autolus Therapeutics Company Information Table 66. Autolus Therapeutics Business Overview Table 67. Autolus Therapeutics Cell Immunotherapy Platform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Autolus Therapeutics Cell Immunotherapy Platform Product Portfolio Table 69. Autolus Therapeutics Recent Development Table 70. Legend Biotech Company Information Table 71. Legend Biotech Business Overview Table 72. Legend Biotech Cell Immunotherapy Platform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Legend Biotech Cell Immunotherapy Platform Product Portfolio Table 74. Legend Biotech Recent Development Table 75. Celltrion Company Information Table 76. Celltrion Business Overview Table 77. Celltrion Cell Immunotherapy Platform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Celltrion Cell Immunotherapy Platform Product Portfolio Table 79. Celltrion Recent Development Table 80. North America Cell Immunotherapy Platform Revenue by Type (2021-2026) & (US$ Million) Table 81. North America Cell Immunotherapy Platform Revenue by Type (2027-2032) & (US$ Million) Table 82. North America Cell Immunotherapy Platform Revenue by Application (2021-2026) & (US$ Million) Table 83. North America Cell Immunotherapy Platform Revenue by Application (2027-2032) & (US$ Million) Table 84. North America Cell Immunotherapy Platform Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 85. North America Cell Immunotherapy Platform Revenue by Country (2021-2026) & (US$ Million) Table 86. North America Cell Immunotherapy Platform Revenue by Country (US$ Million) & (2027-2032) Table 87. Europe Cell Immunotherapy Platform Revenue by Type (2021-2026) & (US$ Million) Table 88. Europe Cell Immunotherapy Platform Revenue by Type (2027-2032) & (US$ Million) Table 89. Europe Cell Immunotherapy Platform Revenue by Application (2021-2026) & (US$ Million) Table 90. Europe Cell Immunotherapy Platform Revenue by Application (2027-2032) & (US$ Million) Table 91. Europe Cell Immunotherapy Platform Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. Europe Cell Immunotherapy Platform Revenue by Country (2021-2026) & (US$ Million) Table 93. Europe Cell Immunotherapy Platform Revenue by Country (US$ Million) & (2027-2032) Table 94. China Cell Immunotherapy Platform Revenue by Type (2021-2026) & (US$ Million) Table 95. China Cell Immunotherapy Platform Revenue by Type (2027-2032) & (US$ Million) Table 96. China Cell Immunotherapy Platform Revenue by Application (2021-2026) & (US$ Million) Table 97. China Cell Immunotherapy Platform Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia Cell Immunotherapy Platform Revenue by Type (2021-2026) & (US$ Million) Table 99. Asia Cell Immunotherapy Platform Revenue by Type (2027-2032) & (US$ Million) Table 100. Asia Cell Immunotherapy Platform Revenue by Application (2021-2026) & (US$ Million) Table 101. Asia Cell Immunotherapy Platform Revenue by Application (2027-2032) & (US$ Million) Table 102. Asia Cell Immunotherapy Platform Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 103. Asia Cell Immunotherapy Platform Revenue by Region (US$ Million) & (2021-2026) Table 104. Asia Cell Immunotherapy Platform Revenue by Region (US$ Million) & (2027-2032) Table 105. SAMEA Cell Immunotherapy Platform Revenue by Type (2021-2026) & (US$ Million) Table 106. SAMEA Cell Immunotherapy Platform Revenue by Type (2027-2032) & (US$ Million) Table 107. SAMEA Cell Immunotherapy Platform Revenue by Application (2021-2026) & (US$ Million) Table 108. SAMEA Cell Immunotherapy Platform Revenue by Application (2027-2032) & (US$ Million) Table 109. SAMEA Cell Immunotherapy Platform Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. SAMEA Cell Immunotherapy Platform Revenue by Country (2021-2026) & (US$ Million) Table 111. SAMEA Cell Immunotherapy Platform Revenue by Country (US$ Million) & (2027-2032) Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Cell Immunotherapy Platform Image Figure 2. Global Cell Immunotherapy Platform Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cell Immunotherapy Platform Market Size Share 2021 VS 2025 VS 2032 Figure 4. Autologous Immune Cell Therapy Image Figure 5. Allogeneic Immune Cell Therapy Image Figure 6. Global Cell Immunotherapy Platform Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Cell Immunotherapy Platform Market Size Share 2021 VS 2025 VS 2032 Figure 8. Immunotherapy Industry Image Figure 9. Biopharmaceutical Industry Image Figure 10. Others Image Figure 11. Global Cell Immunotherapy Platform Market Size (US$ Million) & (2021-2032) Figure 12. Global Cell Immunotherapy Platform Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Cell Immunotherapy Platform Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Cell Immunotherapy Platform Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Cell Immunotherapy Platform Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Cell Immunotherapy Platform Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Cell Immunotherapy Platform Revenue Market Share by Type (2021-2032) Figure 19. Global Cell Immunotherapy Platform Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Cell Immunotherapy Platform Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Cell Immunotherapy Platform Revenue Market Share by Application (2021-2032) Figure 22. North America Cell Immunotherapy Platform Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Cell Immunotherapy Platform Revenue Share by Type (2021-2032) Figure 24. North America Cell Immunotherapy Platform Revenue Share by Application (2021-2032) Figure 25. North America Cell Immunotherapy Platform Revenue Share by Country (2021-2032) Figure 26. United States Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Cell Immunotherapy Platform Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Cell Immunotherapy Platform Revenue Share by Type (2021-2032) Figure 31. Europe Cell Immunotherapy Platform Revenue Share by Application (2021-2032) Figure 32. Europe Cell Immunotherapy Platform Revenue Share by Country (2021-2032) Figure 33. Germany Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Cell Immunotherapy Platform Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Cell Immunotherapy Platform Revenue Share by Type (2021-2032) Figure 43. China Cell Immunotherapy Platform Revenue Share by Application (2021-2032) Figure 44. Asia Cell Immunotherapy Platform Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Cell Immunotherapy Platform Revenue Share by Type (2021-2032) Figure 46. Asia Cell Immunotherapy Platform Revenue Share by Application (2021-2032) Figure 47. Asia Cell Immunotherapy Platform Revenue Share by Region (2021-2032) Figure 48. Japan Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Cell Immunotherapy Platform Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Cell Immunotherapy Platform Revenue Share by Type (2021-2032) Figure 56. SAMEA Cell Immunotherapy Platform Revenue Share by Application (2021-2032) Figure 57. SAMEA Cell Immunotherapy Platform Revenue Share by Country (2021-2032) Figure 58. Brazil Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Cell Immunotherapy Platform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Autologous Immune Cell Therapy
  • Allogeneic Immune Cell Therapy
Applications
  • Immunotherapy Industry
  • Biopharmaceutical Industry
  • Others
Companies covered
  • Kite Pharma
  • Novartis
  • Bristol Myers Squibb
  • Gilead Sciences
  • Bluebird Bio
  • Celyad Oncology
  • Autolus Therapeutics
  • Legend Biotech
  • Celltrion

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cell Immunotherapy Platform Market by Type
  3. 1.2.1 Global Cell Immunotherapy Platform Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Autologous Immune Cell Therapy
  5. 1.2.3 Allogeneic Immune Cell Therapy
  6. 1.3 Cell Immunotherapy Platform Market by Application
  7. 1.3.1 Global Cell Immunotherapy Platform Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Immunotherapy Industry
  9. 1.3.3 Biopharmaceutical Industry
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Cell Immunotherapy Platform Market Dynamics
  1. 2.1 Cell Immunotherapy Platform Industry Trends
  2. 2.2 Cell Immunotherapy Platform Industry Drivers
  3. 2.3 Cell Immunotherapy Platform Industry Opportunities and Challenges
  4. 2.4 Cell Immunotherapy Platform Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Cell Immunotherapy Platform Market Perspective (2021-2032)
  2. 3.2 Global Cell Immunotherapy Platform Growth Trends by Region
  3. 3.2.1 Global Cell Immunotherapy Platform Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cell Immunotherapy Platform Market Size by Region (2021-2026)
  5. 3.2.3 Global Cell Immunotherapy Platform Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Cell Immunotherapy Platform Revenue by Players
  2. 4.1.1 Global Cell Immunotherapy Platform Revenue by Players (2021-2026)
  3. 4.1.2 Global Cell Immunotherapy Platform Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Cell Immunotherapy Platform Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cell Immunotherapy Platform Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Cell Immunotherapy Platform Key Players Headquarters & Area Served
  7. 4.4 Global Cell Immunotherapy Platform Players, Product Type & Application
  8. 4.5 Global Cell Immunotherapy Platform Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Cell Immunotherapy Platform Market CR5 and HHI
  11. 4.6.3 2025 Cell Immunotherapy Platform Tier 1, Tier 2, and Tier 3
5 Cell Immunotherapy Platform Market Size by Type
  1. 5.1 Global Cell Immunotherapy Platform Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Cell Immunotherapy Platform Revenue by Type (2021-2032)
  3. 5.3 Global Cell Immunotherapy Platform Revenue Market Share by Type (2021-2032)
6 Cell Immunotherapy Platform Market Size by Application
  1. 6.1 Global Cell Immunotherapy Platform Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Cell Immunotherapy Platform Revenue by Application (2021-2032)
  3. 6.3 Global Cell Immunotherapy Platform Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Kite Pharma
  2. 7.1.1 Kite Pharma Company Information
  3. 7.1.2 Kite Pharma Business Overview
  4. 7.1.3 Kite Pharma Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Kite Pharma Cell Immunotherapy Platform Product Portfolio
  6. 7.1.5 Kite Pharma Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Cell Immunotherapy Platform Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Bristol Myers Squibb
  14. 7.3.1 Bristol Myers Squibb Company Information
  15. 7.3.2 Bristol Myers Squibb Business Overview
  16. 7.3.3 Bristol Myers Squibb Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bristol Myers Squibb Cell Immunotherapy Platform Product Portfolio
  18. 7.3.5 Bristol Myers Squibb Recent Developments
  19. 7.4 Gilead Sciences
  20. 7.4.1 Gilead Sciences Company Information
  21. 7.4.2 Gilead Sciences Business Overview
  22. 7.4.3 Gilead Sciences Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Gilead Sciences Cell Immunotherapy Platform Product Portfolio
  24. 7.4.5 Gilead Sciences Recent Developments
  25. 7.5 Bluebird Bio
  26. 7.5.1 Bluebird Bio Company Information
  27. 7.5.2 Bluebird Bio Business Overview
  28. 7.5.3 Bluebird Bio Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bluebird Bio Cell Immunotherapy Platform Product Portfolio
  30. 7.5.5 Bluebird Bio Recent Developments
  31. 7.6 Celyad Oncology
  32. 7.6.1 Celyad Oncology Company Information
  33. 7.6.2 Celyad Oncology Business Overview
  34. 7.6.3 Celyad Oncology Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Celyad Oncology Cell Immunotherapy Platform Product Portfolio
  36. 7.6.5 Celyad Oncology Recent Developments
  37. 7.7 Autolus Therapeutics
  38. 7.7.1 Autolus Therapeutics Company Information
  39. 7.7.2 Autolus Therapeutics Business Overview
  40. 7.7.3 Autolus Therapeutics Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Autolus Therapeutics Cell Immunotherapy Platform Product Portfolio
  42. 7.7.5 Autolus Therapeutics Recent Developments
  43. 7.8 Legend Biotech
  44. 7.8.1 Legend Biotech Company Information
  45. 7.8.2 Legend Biotech Business Overview
  46. 7.8.3 Legend Biotech Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Legend Biotech Cell Immunotherapy Platform Product Portfolio
  48. 7.8.5 Legend Biotech Recent Developments
  49. 7.9 Celltrion
  50. 7.9.1 Celltrion Company Information
  51. 7.9.2 Celltrion Business Overview
  52. 7.9.3 Celltrion Cell Immunotherapy Platform Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Celltrion Cell Immunotherapy Platform Product Portfolio
  54. 7.9.5 Celltrion Recent Developments
8 North America
  1. 8.1 North America Cell Immunotherapy Platform Revenue (2021-2032)
  2. 8.2 North America Cell Immunotherapy Platform Revenue by Type (2021-2032)
  3. 8.2.1 North America Cell Immunotherapy Platform Revenue by Type (2021-2026)
  4. 8.2.2 North America Cell Immunotherapy Platform Revenue by Type (2027-2032)
  5. 8.3 North America Cell Immunotherapy Platform Revenue Share by Type (2021-2032)
  6. 8.4 North America Cell Immunotherapy Platform Revenue by Application (2021-2032)
  7. 8.4.1 North America Cell Immunotherapy Platform Revenue by Application (2021-2026)
  8. 8.4.2 North America Cell Immunotherapy Platform Revenue by Application (2027-2032)
  9. 8.5 North America Cell Immunotherapy Platform Revenue Share by Application (2021-2032)
  10. 8.6 North America Cell Immunotherapy Platform Revenue by Country
  11. 8.6.1 North America Cell Immunotherapy Platform Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Cell Immunotherapy Platform Revenue by Country (2021-2026)
  13. 8.6.3 North America Cell Immunotherapy Platform Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Cell Immunotherapy Platform Revenue (2021-2032)
  2. 9.2 Europe Cell Immunotherapy Platform Revenue by Type (2021-2032)
  3. 9.2.1 Europe Cell Immunotherapy Platform Revenue by Type (2021-2026)
  4. 9.2.2 Europe Cell Immunotherapy Platform Revenue by Type (2027-2032)
  5. 9.3 Europe Cell Immunotherapy Platform Revenue Share by Type (2021-2032)
  6. 9.4 Europe Cell Immunotherapy Platform Revenue by Application (2021-2032)
  7. 9.4.1 Europe Cell Immunotherapy Platform Revenue by Application (2021-2026)
  8. 9.4.2 Europe Cell Immunotherapy Platform Revenue by Application (2027-2032)
  9. 9.5 Europe Cell Immunotherapy Platform Revenue Share by Application (2021-2032)
  10. 9.6 Europe Cell Immunotherapy Platform Revenue by Country
  11. 9.6.1 Europe Cell Immunotherapy Platform Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Cell Immunotherapy Platform Revenue by Country (2021-2026)
  13. 9.6.3 Europe Cell Immunotherapy Platform Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Cell Immunotherapy Platform Revenue (2021-2032)
  2. 10.2 China Cell Immunotherapy Platform Revenue by Type (2021-2032)
  3. 10.2.1 China Cell Immunotherapy Platform Revenue by Type (2021-2026)
  4. 10.2.2 China Cell Immunotherapy Platform Revenue by Type (2027-2032)
  5. 10.3 China Cell Immunotherapy Platform Revenue Share by Type (2021-2032)
  6. 10.4 China Cell Immunotherapy Platform Revenue by Application (2021-2032)
  7. 10.4.1 China Cell Immunotherapy Platform Revenue by Application (2021-2026)
  8. 10.4.2 China Cell Immunotherapy Platform Revenue by Application (2027-2032)
  9. 10.5 China Cell Immunotherapy Platform Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cell Immunotherapy Platform Revenue (2021-2032)
  2. 11.2 Asia Cell Immunotherapy Platform Revenue by Type (2021-2032)
  3. 11.2.1 Asia Cell Immunotherapy Platform Revenue by Type (2021-2026)
  4. 11.2.2 Asia Cell Immunotherapy Platform Revenue by Type (2027-2032)
  5. 11.3 Asia Cell Immunotherapy Platform Revenue Share by Type (2021-2032)
  6. 11.4 Asia Cell Immunotherapy Platform Revenue by Application (2021-2032)
  7. 11.4.1 Asia Cell Immunotherapy Platform Revenue by Application (2021-2026)
  8. 11.4.2 Asia Cell Immunotherapy Platform Revenue by Application (2027-2032)
  9. 11.5 Asia Cell Immunotherapy Platform Revenue Share by Application (2021-2032)
  10. 11.6 Asia Cell Immunotherapy Platform Revenue by Country
  11. 11.6.1 Asia Cell Immunotherapy Platform Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Cell Immunotherapy Platform Revenue by Country (2021-2026)
  13. 11.6.3 Asia Cell Immunotherapy Platform Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cell Immunotherapy Platform Revenue (2021-2032)
  2. 12.2 SAMEA Cell Immunotherapy Platform Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Cell Immunotherapy Platform Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Cell Immunotherapy Platform Revenue by Type (2027-2032)
  5. 12.3 SAMEA Cell Immunotherapy Platform Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Cell Immunotherapy Platform Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Cell Immunotherapy Platform Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Cell Immunotherapy Platform Revenue by Application (2027-2032)
  9. 12.5 SAMEA Cell Immunotherapy Platform Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Cell Immunotherapy Platform Revenue by Country
  11. 12.6.1 SAMEA Cell Immunotherapy Platform Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Cell Immunotherapy Platform Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Cell Immunotherapy Platform Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst